Indivior PLC Ordinary Shares
$ 32.97
4.34%
14 Apr - close price
- Market Cap 3,952,062,000 USD
- Current Price $ 32.97
- High / Low $ 32.97 / 31.66
- Stock P/E 19.27
- Book Value -0.78
- EPS 1.64
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 0.12 %
- 52 Week High 38.00
- 52 Week Low 8.69
About
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Analyst Target Price
$46.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-09 | 2025-02-20 | 2024-10-24 | 2024-07-25 | 2024-04-25 | 2024-02-22 | 2023-11-09 | 2023-07-27 | 2023-04-27 |
| Reported EPS | 0.82 | 0.72 | 0.51 | 0.41 | 0.3189 | 0.03 | -0.79 | 0.37 | 0.43 | -0.98 | 0.39 | 0.4 |
| Estimated EPS | 0.674 | 0.39 | 0.24 | 0.2867 | 0.26 | 0.31 | 0.4 | 0.42 | 0.28 | 0.3 | 0.22 | 0.4 |
| Surprise | 0.146 | 0.33 | 0.27 | 0.1233 | 0.0589 | -0.28 | -1.19 | -0.05 | 0.15 | -1.28 | 0.17 | 0 |
| Surprise Percentage | 21.6617% | 84.6154% | 112.5% | 43.0066% | 22.6538% | -90.3226% | -297.5% | -11.9048% | 53.5714% | -426.6667% | 77.2727% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.64 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.095 | $0.032 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INDV
2026-04-09 15:10:00
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) announced it will release its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release, the company's leadership team will host a live webcast presentation at 8:00 a.m. U.S. EDT to discuss the results. Access to the webcast and replay will be available through the "Investors" section of Indivior's website.
2026-04-09 12:40:22
Indivior PLC specializes in addiction treatments, particularly for opioid use disorder, with products like SUBLOCADE and Sublimaze. The company focuses on long-acting injectables to improve patient adherence and reduce relapse risks. Despite potential risks like patent cliffs and competition, analysts see growth potential due to increasing global demand for addiction solutions and policy shifts favoring medication-assisted treatment.
2026-04-09 12:09:02
Indivior PLC specializes in addiction treatments, particularly for opioid use disorder, with products like SUBLOCADE and Sublimaze. The company focuses on long-acting injectables, which is critical in a global market driven by opioid crises. Indivior's strategy positions it as a key player in healthcare, offering investors exposure to a growing niche with potential for expansion into adjacent markets.
2026-04-04 15:40:00
This article provides a financial overview of Indivior Pharmaceuticals, Inc (INDV), detailing its revenue breakdown, profitability margins, and a comparison with competitors. SUBLOCADE is identified as the largest revenue contributor, and the company's gross margin stands at 73.57%. The article also benchmarks INDV's financial performance against industry leaders like ACAD and SYRE.
2026-03-30 10:09:30
Hennion & Walsh Asset Management Inc. significantly increased its stake in Indivior PLC by 43.4%, purchasing an additional 96,177 shares to hold a total of 317,600 shares valued at $11.395 million. This move is supported by accelerated insider buying activity in early January and broadly positive analyst ratings, with an average price target of $39.33. Indivior recently surpassed quarterly EPS and revenue estimates, further bolstering investor confidence.
2026-03-29 12:10:57
SG Americas Securities LLC significantly increased its stake in Indivior PLC by 752.2% in Q4, acquiring 363,829 shares to now hold 412,197 shares valued at approximately $14.79 million. Company insiders also showed confidence, purchasing 5,842 shares worth about $203,342 in the last three months, including directors Daniel Ninivaggi and David Wheadon. Indivior surpassed EPS and revenue estimates in its recent quarter, leading analysts to maintain an average "Buy" rating with a consensus target price of $39.33.
